ConductScience.org, home

Comparison · NCT03493685-deaths

Sparsentan vs Irbesartan: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Sparsentan vs Irbesartan: deaths from any cause. Trial comparisons, record NCT03493685-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03493685-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02170.008490.0546wilson
Risk in group 20.0160.005470.0461wilson
Risk difference, group 1 minus group 20.0057-0.02720.0402newcombe hybrid score
Risk ratio, group 1 over group 21.360.3085.97log
Odds ratio, group 1 over group 21.360.3016.18log
Number needed to harm, for one more death from any cause on Sparsentan than on Irbesartan176from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Sparsentan
Participants in this arm were randomized to receive initial dose of Sparsentan as 400 milligrams (mg) over-encapsulated (blinded) with size 00 capsules orally once daily. A dose adjustment was made for participants whose body weight was ≤50 kilograms (kg) at screening; these participants received one-half of the specified dose of Sparsentan. The dose was then titrated to achieve the maximum daily target dose of 800 mg.
4184EG000
Group 2Irbesartan
Participants were randomized to receive active control doses of Irbesartan 150 mg over-encapsulated (blinded) with size 00 capsules orally once daily. A dose adjustment was made for participants whose body weight was ≤50 kg at screening; these participants received one-half of the specified dose of Irbesartan. The dose was then titrated to achieve the maximum daily target dose of 300 mg.
3187EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Up to Week 112

Source ClinicalTrials.gov

Trial

Title
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT number
NCT03493685
Phases
PHASE3
Conditions
Focal Segmental Glomerulosclerosis
Interventions
sparsentan, Irbesartan
Lead sponsor
Travere Therapeutics, Inc.
Results first posted
2024-04-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03493685-deaths